Liver disease in management and outcomes of European and Asian patients with atrial fibrillation: A report from two observational prospective registries
In AF, LD is associated with reduced OAC prescription, especially in Europe, and a higher risk of adverse outcomes, particularly in patients not receiving OAC, with no significant differences between European and Asian cohorts.
Authors
- Bernadette Corica (ORCID: https://orcid.org/0000-0001-9460-4435)
- Alena Shantsila (ORCID: https://orcid.org/0000-0002-0594-8576)
- Davide Antonio Mei (ORCID: https://orcid.org/0009-0000-6345-3742)
- Hung‐Fat Tse
- Tommaso Bucci
- Gregory Y. H. Lip
- Tze‐Fan Chao
- Marco Proietti
- Giulio Francesco Romiti
- Giuseppe Boriani
Institutions
- University of Modena and Reggio Emilia (IT)
- Medical University of Białystok (PL)
- University of Liverpool (GB)
- National Yang Ming Chiao Tung University (TW)
- University of Milan (IT)
- Queen Mary Hospital (CN)
- Taipei Veterans General Hospital (TW)
- Liverpool Heart and Chest Hospital (GB)
- Istituti Clinici Scientifici Maugeri (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Liverpool John Moores University (GB)
- Sapienza University of Rome (IT)
- University of Hong Kong (HK)
- Aalborg University (DK)
Publication Details
- Journal
- European Journal of Clinical Investigation
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1111/eci.70193
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00